Retension Pharmaceuticals, Inc. (RTSN)
| Market Cap | 101.73M |
| Revenue (ttm) | n/a |
| Net Income | -14.24M |
| EPS | -17.67 |
| Shares Out | 8.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,024 |
| Open | 11.56 |
| Previous Close | 11.64 |
| Day's Range | 11.56 - 12.86 |
| 52-Week Range | 9.66 - 12.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About RTSN
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
Financial Performance
Financial StatementsNews
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing med...
Biotech IPOs Charge Ahead as Tech Deals Stall
TRex Bio and Retension Pharmaceuticals are set to continue the industry's public debut rebound.
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Hypertension drug developer Retension Pharmaceuticals files for a $58 million IPO
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
Retension Pharmaceuticals IPO Registration Document (S-1)
Retension Pharmaceuticals has filed to go public with an IPO on the NASDAQ